Patent application number | Description | Published |
20090246852 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 10-01-2009 |
20100266613 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of TNF-α. | 10-21-2010 |
20100322931 | ANTI-VEGF ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF. | 12-23-2010 |
20110117110 | ANTI-EGFR ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR. | 05-19-2011 |
20110177095 | ANTI-HER2 ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2. | 07-21-2011 |
20120064067 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 03-15-2012 |
20120064068 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 03-15-2012 |
20120064069 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 03-15-2012 |
20120070440 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 03-22-2012 |
20120135005 | ANTI-TNF-a ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 05-31-2012 |
20140212424 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 07-31-2014 |